Clinical trials: Blood Pressures
Hypertension
Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension
The purpose is to determine the effective dosage and to study the effects of this dosage taken for 12 days on systolic and diastolic blood pressure in patients with hypertension.
- Trial name
- NCT00562549
- Testing
- SLx-2101
- Where
- United Kingdom
- Volunteers
- 26 people
- Sponsor
- Retension Pharmaceuticals. Inc.
Blood Pressure, Blood Pressure Variability
This Study Aims to Assess the Performances of Optical Blood Pressure Monitoring Device, tBPC Product With Reference to ISO 81060-3:2022
In this study, according to the latest released ISO 81060-3:2022 standard requirements, non-invasive blood pressure measurement by cuff at the start and the end time points will be used as oCareTM BP100 start-to-end blood…
- Trial name
- NCT06815614
- Testing
- A Photoplethysmography-Based Continuous Automated Non-Invasive Sphygmomanometer
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- Taiwan Biophotonic Corporation
Hypertension
Efficacy and Safety of Aliskiren in Patients With Mild to Moderate Hypertension During Exercise
This study compared the blunting effect of aliskiren and valsartan monotherapies on exercise-induced rises in systolic blood pressure in patients with mild to moderate essential hypertension.
- Trial name
- NCT00819767
- Testing
- Aliskiren, Valsartan
- Where
- 8 sites in Czechia, Hungary and 2 more
- Volunteers
- 68 people
- Sponsor
- Novartis
Hypertension
A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
The study is designed to compare the effects of nebivolol (10, 20, 40mg/day) with another beta blocker, extended-release metoprolol, at a range of doses.
- Trial name
- NCT00648895
- Testing
- Nebivolol, Metoprolol ER (TM)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Forest Laboratories
Hypertension, Dyslipidemia
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
This study was to evaluate the therapeutic effect and safety of amosartan Q tablet administration in adult patients with hypertension and dyslipidemia.
- Trial name
- NCT05450575
- Testing
- Amosartan Q tablet
- Where
- South Korea
- Volunteers
- 5,400 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Peripheral Vascular Disease, Intermittent Claudication
Intermittent Negative Pressure; Impact on Peripheral Artery Disease and Intermittent Claudication
The objective is to ensure the pro-active collection of information on quality, safety and performance of FlowOx™ after it is placed on the market.
- Conditions
- Peripheral Vascular Disease, Intermittent Claudication, Walking, Difficulty, Critical Limb Ischemia
- Trial name
- FlowOx (NCT04100681)
- Testing
- Active FlowOx™
- Where
- 5 sites in Germany
- Volunteers
- 16 people
- Sponsor
- Otivio AS
High Blood Pressure, Migraine Headaches
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
- Conditions
- High Blood Pressure, Migraine Headaches, Chest Pain
- Trial name
- NCT00960245
- Testing
- Nadolol (1 x 80 mg) Tablets (Invamed, Inc), Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sandoz
Prehypertension
A Clinical Trial of an Herbal Liquid Supplement - 'DBPS' for Managing Blood Pressure
Prehypertension is a clinical condition characterized by systolic blood pressure (SBP) readings between 120 and 139 mmHg and/or diastolic blood pressure (DBP) readings between 80 and 89 mmHg, as per the Joint National Committee…
- Trial name
- NCT07629570
- Testing
- DBPS
- Where
- 4 sites in India
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- Eetho Brands, Inc
Blood Pressure
Optical System to Continuously Measure Arterial Blood Pressure
Comparison of an optical method to continuously measure blood pressure against an invasive arterial catheter.
- Trial name
- BP (NCT02651558)
- Testing
- Experimental: OBPM 2015-MD-0022 - CHEST, Experimental: OBPM 2015-MD-0022 - CHEST & FINGER, Experimental: OBPM 2015-MD-0022 - FINGER
- Where
- Switzerland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- CSEM Centre Suisse d'Electronique et de Microtechnique SA - Recherche et Developpement
Essential Hypertension
Efficacy and Safety of LCZ696 200 mg + Amlodipine 5 mg in Comparison With Amlodipine 5 mg in Hypertensive Patients Not Responding to Amlodipine
This study will assess whether LCZ696 when used in combination with amlodipine will provide greater BP lowering benefit compared to amlodipine alone in Asian hypertensive patients not adequately responsive to amlodipine therapy.
- Trial name
- NCT01663233
- Testing
- LCZ696, Amlodipine
- Where
- 28 sites in China, Japan and 4 more
- Volunteers
- 266 people
- Sponsor
- Novartis Pharmaceuticals
Blood Pressure
Clinical Trial of Wrist Blood Pressure Monitor in Conformance With the EN ISO 81060-2:2019/A1:2020 Standard
The accuracy and safety of wrist blood pressure (model: MLY-B10) is evaluated according to the requirement of EN ISO 81060-2:2019/A1:2020.
- Trial name
- NCT05482035
- Testing
- wrist blood pressure monitor
- Where
- China
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Huawei Device Co., Ltd
Hypertension, Heart Failure
Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)
The purpose of this study was to evaluate the efficacy and safety of intravenous (IV) clevidipine as compared with standard of care IV antihypertensive agents for blood pressure (BP) lowering in patients with acute heart failure…
- Trial name
- PRONTO (NCT00803634)
- Testing
- Clevidipine, Standard of Care IV antihypertensive
- Where
- 13 sites in United States, France and 1 more
- Volunteers
- 117 people
- Sponsor
- The Medicines Company
Uncontrolled Hypertension, Resistant Hypertension
A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
This is a Phase III, multicentre, randomised, double-blinded, placebo-controlled, parallel group study to evaluate the safety, tolerability and effect of 1 or 2 mg baxdrostat versus placebo, administered once daily (QD) orally…
- Trial name
- BaxHTN (NCT06034743)
- Testing
- Baxdrostat
- Where
- 263 sites in United States, Argentina and 27 more
- Volunteers
- 796 people
- Sponsor
- AstraZeneca
Blood Pressure
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
- Trial name
- NCT05215418
- Testing
- VI-0521, Phentermine
- Where
- 28 sites in United States
- Volunteers
- 565 people
- Sponsor
- VIVUS LLC
Hypertension, Portal, Liver Cirrhosis
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes.
- Trial name
- NCT06082843
- Testing
- Avenciguat
- Where
- 15 sites in United States, Austria and 8 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential…
- Trial name
- NCT06130124
- Where
- South Korea
- Volunteers
- 5,000 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Hypertension
A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients
- Trial name
- NCT04521023
- Testing
- Cantabell Tab, Candemore Plus Tab
- Where
- 14 sites in South Korea
- Volunteers
- 132 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
Long Term Study of Valsartan and Amlodipine in Patients With Essential Hypertension (Extension to Study CVAA489A1301)
The purpose of this study is to evaluate long-term safety and tolerability of once daily administration of the combination of Valsartan and Amlodipine 80/5 mg for 52 weeks in patients with essential hypertension.
- Trial name
- NCT00446524
- Testing
- Valsartan + Amlodipine besilate
- Where
- Japan
- Volunteers
- 403 people
- Sponsor
- Novartis
Essential Hypertension
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension
Both Olmesartan (OLM)/Amlodipine (AML) combination and Hydrochlorothiazide (HCTZ) have proven to be efficacious and safe in lowering blood pressure, but may not always be sufficient.
- Trial name
- NCT00902538
- Testing
- Olmesartan medoxomil 40 mg - Amlodipine 10 mg, Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg, Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg
- Where
- 117 sites in Austria, Belgium and 12 more
- Volunteers
- 2,204 people
- Sponsor
- Daiichi Sankyo
Hypertension
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.
Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension
- Trial name
- NCT00219128
- Testing
- aliskiren
- Where
- United States
- Volunteers
- 671 people
- Sponsor
- Novartis